New pill aims to tackle fatty liver, diabetes, and high cholesterol in one go
NCT ID NCT05464784
First seen Feb 05, 2026 · Last updated May 10, 2026 · Updated 11 times
Summary
This phase 2 study tests an experimental drug called MN-001 (tipelukast) in 40 adults with non-alcoholic fatty liver disease, type 2 diabetes, and high triglycerides. Participants take either the drug or a placebo daily for 24 weeks. The main goals are to see if the drug reduces liver fat and lowers blood triglycerides. The study is active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jubilee Clinical Research, Inc.
Las Vegas, Nevada, 89106, United States
-
Pinnacle Clinical Research at South Texas Research Institute
Edinburg, Texas, 78539, United States
Conditions
Explore the condition pages connected to this study.